Emalex Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Emalex Biosciences sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Emalex Biosciences: 14 sponsored US clinical trials, none currently recruiting.

Emalex Biosciences sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Childhood-Onset Fluency Disorder (Stuttering), with 1 trials.

Top-decile sponsor footprint

Emalex Biosciences ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522
COMPLETED Phase 1

Food-effect Study of Ecopipam Pharmacokinetics

NCT06669091
COMPLETED Phase 1

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160
COMPLETED Phase 3

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

NCT05615220
COMPLETED Phase 1

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
COMPLETED Phase 1

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
TERMINATED Phase 1

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
COMPLETED Phase 2

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956
COMPLETED Phase 2

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

NCT04114539
COMPLETED Phase 2

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

NCT04007991
COMPLETED Phase 2

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

NCT02102698
TERMINATED Phase 3

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

NCT01751802
COMPLETED Phase 1

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

NCT01408394
COMPLETED Phase 2

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

NCT01215357

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 5
Phase 3 3

Therapeutic Areas

Childhood-Onset Fluency Disorder (Stuttering) 1
Tourette Syndrome 1
Healthy 1

How the Emalex Biosciences early-phase archive is shaped

14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).

Phase mix: 3 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Childhood-Onset Fluency Disorder (Stuttering) (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Emalex Biosciences: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Emalex Biosciences3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emalex Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Emalex Biosciences page

14 registered trials is a research-attention snapshot, not an endorsement of Emalex Biosciences or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emalex Biosciences pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.